Table 3 Clinical characteristics of patients with initial normal endothelial function who improved vs. those who did not improve after 3 months of enrollment treatment.
From: Effect of early endothelial function improvement on subclinical target organ damage in hypertensives
Variables | Improved group (n = 110) | Unimproved group (n = 166) | P value |
|---|---|---|---|
Female, n (%) | 44 (40.00%) | 84 (50.60%) | 0.084 |
Age (years) | 55.22 ± 11.91 | 63.35 ± 11.01 | < 0.001 |
Current smoking [n (%)] | 19 (17.27%) | 45 (27.11%) | 0.058 |
Drinking [n (%)] | 8 (7.27%) | 22 (13.25%) | 0.172 |
Duration of EH (months) | 1 (0- 7) | 2 (0- 10) | 0.250 |
Diabetes mellitus [n (%)] | 9 (8.65%) | 15 (9.32%) | 1.000 |
BMI (kg/m2) | 23.99 ± 23.99 | 24.05 ± 2.94 | 0.876 |
SBP (mmHg) | 151.0 ± 10.23 | 150.18 ± 10.03 | 0.487 |
DBP (mmHg) | 86.66 ± 12.72 | 83.9 ± 11.23 | 0.059 |
Heart rate (bp) | 72.64 ± 8.3 | 72.36 ± 8.79 | 0.795 |
TBil (μmol/L) | 14.33 ± 6.84 | 14.0 ± 5.42 | 0.745 |
ALT (U/L) | 23 (17—32) | 23 (17—33) | 0.876 |
LDH (U/L) | 171.53 ± 38.12 | 176.89 ± 37.19 | 0.263 |
Uric acid (μmol/L) | 332.96 ± 84.43 | 346.2 ± 84.08 | 0.222 |
eGFR (mL/min/1.73m2) | 96.44 ± 14.52 | 87.29 ± 14.32 | < 0.001 |
Total cholesterol (mmol/L) | 4.86 ± 1.08 | 5.13 ± 1.15 | 0.063 |
HDL-C (mmol/L) | 1.39 ± 0.40 | 1.36 ± 0.39 | 0.468 |
LDL-C (mmol/L) | 2.98 ± 0.82 | 3.19 ± 1.07 | 0.098 |
FSG (mmol/L) | 5.66 ± 1.07 | 5.7 ± 1.28 | 0.784 |
CIMT (cm) | 0.06 ± 0.01 | 0.06 ± 0.01 | 0.352 |
UACR (mg/g) | 7.44 (3.99—13.90) | 7.47 (4.18—12.23) | 0.846 |
BP compliance [n (%)] | 102 (92.73%) | 152 (91.57%) | 0.727 |
LVMI (g/m2) | 79.48 ± 17.92 | 80.19 ± 16.53 | 0.763 |
ACEI/ARBs [n (%)] | 59 (53.64%) | 86 (51.81%) | 0.766 |
β-blockers [n (%)] | 29 (26.36%) | 54 (32.53%) | 0.274 |
Calcium channel blockers [n (%)] | 53 (48.18%) | 85 (51.20%) | 0.623 |
Diuretics [n (%)] | 31 (28.18%) | 49 (29.52%) | 0.811 |
Statin [n (%)] | 38 (34.55%) | 40 (24.10%) | 0.059 |
FMD (%) | 14.16 ± 6.9 | 12.37 ± 4.37 | 0.017 |
